Risk of progression in chronic phase‐chronic myeloid leukemia patients eligible for tyrosine kinase inhibitor discontinuation: Final analysis of the TFR‐PRO study
American Journal of Hematology · 2023
DOI: 10.1002/ajh.27073 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Hematology, 2023. Verfasst von Giovanni Paolo Maria Zambrotta und 27 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy. Hauptthemen laut MEDLINE: Protein Kinase Inhibitors, Leukemia, Myeloid, Chronic-Phase. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Dipartimento di Medicina e Chirurgia, Università degli Studi di Milano-Bicocca, Department of Medicine and Surgery.
Abstract (Originalsprache)
Disease progression to accelerated/blast phase (AP/BP) in patients with chronic phase chronic myeloid leukemia (CP‐CML) after treatment discontinuation (TD) has never been systematically reported in clinical trials. However, recent reports of several such cases has raised concern. To estimate the risk of AP/BP among TD‐eligible patients, we conducted TFR‐PRO, a cohort retro‐prospective study: 870 CP‐CML patients eligible for TD formed a discontinuation cohort (505 patients) and a reference one (365 patients). The primary objective was the time adjusted rate (TAR) of progression in relation to TD. Secondary endpoints included the TAR of molecular relapse, that is, loss of major molecular response (MMR). With a median follow up of 5.5 years and 5188.2 person‐years available, no events occurred in the TD cohort. One event of progression was registered 55 months after the end of TD, when the patient was contributing to the reference cohort. The TAR of progression was 0.019/100 person‐years (95% CI [0.003–0.138]) in the overall group; 0.0 (95% CI [0–0.163]) in the discontinuation cohort; and 0.030 (95% CI [0.004–0.215]) in the reference cohort. These differences are not statistically significant. Molecular relapses occurred in 172/505 (34.1%) patients after TD, and in 64/365 (17.5%) patients in the reference cohort, p < .0001. Similar rates were observed in TD patients in first, second or third line of treatment. CML progression in patients eligible for TD is rare and not related to TD. Fears about the risk of disease progression among patients attempting TD should be dissipated.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy.
- Hematology Department, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy.
- Hématologie clinique & INSEM U1052, Centre Léon Bérard, Lyon, France.
- Department of Medicine and Oncology, Jewish General Hospital, McGill University, Montreal, Quebec, Canada.
- Hematology Division, Research Center, Hôpital Maisonneuve-Rosemont, Université de Montréal, Montreal, Quebec, Canada.
- Division of Hematology, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.
ORCID-Profile: Giovanni Paolo Maria Zambrotta, Franck E Nicolini, Alberto Alvarez-Larran, Alessandra Iurlo, Marco Cerrano, Isabella Capodanno, Sara Galimberti, Rocco Piazza, Carlo Gambacorti-Passerini
Förderung
- Dipartimento di Medicina e Chirurgia, Università degli Studi di Milano-Bicocca
- Department of Medicine and Surgery
Zitieren
APA
Zambrotta, G. P. M., Nicolini, F. E., Assouline, S., Busque, L., Pungolino, E., Abruzzese, E., Miggiano, M. C., Elena, C., Alvarez-Larran, A., Triguero, A., Iurlo, A., Bucelli, C., Cerrano, M., Capodanno, I., Lunghi, F., le Coutre, P., Galimberti, S., Caocci, G., Maffioli, M., …, & Gambacorti-Passerini, C. (2023). Risk of progression in chronic phase‐chronic myeloid leukemia patients eligible for tyrosine kinase inhibitor discontinuation: Final analysis of the TFR‐PRO study. American Journal of Hematology. https://doi.org/10.1002/ajh.27073
Vancouver
Zambrotta GPM, Nicolini FE, Assouline S, Busque L, Pungolino E, Abruzzese E, et al. Risk of progression in chronic phase‐chronic myeloid leukemia patients eligible for tyrosine kinase inhibitor discontinuation: Final analysis of the TFR‐PRO study. American Journal of Hematology. 2023. doi:10.1002/ajh.27073
BibTeX
@article{Zambrotta2023,
author = {Zambrotta, Giovanni Paolo Maria and Nicolini, Franck E and Assouline, Sarit and Busque, Lambert and Pungolino, Ester and Abruzzese, Elisabetta and Miggiano, Maria Cristina and Elena, Chiara and Alvarez-Larran, Alberto and Triguero, Ana and Iurlo, Alessandra and Bucelli, Cristina and Cerrano, Marco and Capodanno, Isabella and Lunghi, Francesca and le Coutre, Philipp and Galimberti, Sara and Caocci, Giovanni and Maffioli, Margherita and Stagno, Fabio and Saussele, Susanne and Piazza, Rocco and Druker, Brian J and Fava, Carmen and Guglielmana, Veronica and Colombo, Federica and Antolini, Laura and Gambacorti-Passerini, Carlo},
title = {Risk of progression in chronic phase‐chronic myeloid leukemia patients eligible for tyrosine kinase inhibitor discontinuation: Final analysis of the TFR‐PRO study},
journal = {American Journal of Hematology},
year = {2023},
doi = {10.1002/ajh.27073}
}
EUVIMED